Herbal medicines for viral myocarditis

Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, 11 Bei San Huan Dong Lu, Chaoyang District, Beijing, China, 100029.
Cochrane database of systematic reviews (Online) (Impact Factor: 6.03). 07/2010; 8(7):CD003711. DOI: 10.1002/14651858.CD003711.pub3
Source: PubMed


Viral myocarditis is a disease where the muscles in the walls of the heart become infected with a virus. Herbal medicines are used as treatment for diseases such as viral myocarditis. Many clinical trials have been conducted to investigate how effective herbal medicines are for viral myocarditis, and this review aimed to find out whether they work. The review authors conducted an extensive search of the medical literature for trials where a herbal medicine was compared with a fake medicine (placebo), no intervention, or conventional medicines for treatment of viral myocarditis. Trials of herbal medicine plus a conventional drug versus the drug alone were also eligible. The review authors only included properly randomised trials, as these produce the most reliable evidence. The literature search identified 20 clinical trials, involving 2177 people, performed and published in China. Examination of these 20 trials did not reveal any benefit of herbal medicine on death from all causes. However, they did show that Astragalus membranaceus (either as an injection or granules) may have a positive effect on heart function as measured by electrocardiogram. Another herbal medicine, Shengmai decoction, improved quality of life measured by a standard questionnaire (the SF-36). Six trials provided information about adverse events, but no serious adverse effects were reported. The methods used in these trials were generally of poor quality, although all 20 trials had adequate sequence generation (randomisation). The evidence from these trials is inconclusive because they were poorly designed and of low-quality, and there was no certainty that all the participants were correctly diagnosed with viral myocarditis. Further randomised trials with a better methods are needed to investigate this area further.

Download full-text


Available from: Jianping Liu, Oct 05, 2015
1 Follower
39 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Olive tree (Olea europaea L.) leaves have been widely used in traditional remedies in European and Mediterranean countries as extracts, herbal teas, and powder. They contain several potentially bioactive compounds that may have hypoglycemic properties. To examine the efficacy of 500 mg oral olive leaf extract taken once daily in tablet form versus matching placebo in improving glucose homeostasis in adults with type 2 diabetes (T2DM). In this controlled clinical trial, 79 adults with T2DM were randomized to treatment with 500 mg olive leaf extract tablet taken orally once daily or matching placebo. The study duration was 14 weeks. Measures of glucose homeostasis including Hba1c and plasma insulin were measured and compared by treatment assignment. In a series of animal models, normal, streptozotocin (STZ) diabetic, and sand rats were used in the inverted sac model to determine the mechanism through which olive leaf extract affected starch digestion and absorption. In the randomized clinical trial, the subjects treated with olive leaf extract exhibited significantly lower HbA1c and fasting plasma insulin levels; however, postprandial plasma insulin levels did not differ significantly by treatment group. In the animal models, normal and STZ diabetic rats exhibited significantly reduced starch digestion and absorption after treatment with olive leaf extract compared with intestine without olive leaf treatment. Reduced digestion and absorption was observed in both the mucosal and serosal sides of the intestine. Though reduced, the decline in starch digestion and absorption did not reach statistical significance in the sand rats. Olive leaf extract is associated with improved glucose homeostasis in humans. Animal models indicate that this may be facilitated through the reduction of starch digestion and absorption. Olive leaf extract may represent an effective adjunct therapy that normalizes glucose homeostasis in individuals with diabetes.
    Journal of medicinal food 04/2012; 15(7):605-10. DOI:10.1089/jmf.2011.0243 · 1.63 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A previous study indicated that Rheb1 is required for mammalian target of TOR complex 1 (mTORC1) signaling in the brain. However, the function of Rheb1 in the heart is still elusive. In the present study, we deleted Rheb1 specifically in cardiomyocytes and found that reduced Rheb1 levels conferred cardioprotection against pathologic remodeling in myocardial infarction (MI) and pressure overload (transverse aortic constriction) mouse models. Cardiomyocyte apoptosis was reduced and mTORC1 activity was suppressed in cardiomyocyte Rheb1-deletion mice, suggesting that Rheb1 regulates mTORC1 activation in myocardium. Furthermore, we demonstrated that astragaloside IV (As-IV) could inhibit mTORC1, and As-IV treatment displayed similar protection against MI and transverse aortic constriction as Rheb1 genetic inhibition. This study indicates that Rheb1 is essential for mTORC1 activation in cardiomyocytes and suggests that targeting Rheb1-mTORC1 signaling, such as by As-IV treatment, may be an effective therapeutic method for treating patients with adverse cardiac remodeling after MI and hypertrophy.
    American Journal Of Pathology 04/2013; 182(6). DOI:10.1016/j.ajpath.2013.02.012 · 4.59 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Shenmai injection (SMI) is widely applied in clinical practice as an organ protector. This overview is to evaluate the current evidence from systematic reviews (SRs) of SMI for healthcare. The literature searches were carried out in 6 databases without language restrictions until December 2012. The quality of the primary studies from the respective SRs was evaluated by using Jadad score. The overview quality assessment questionnaire (OQAQ) was used to evaluate the methodological quality of all included SRs. Twenty eligible SRs were identified. They reported a wide range of conditions, including SMI for cardio/cerebrovascular diseases, viral myocarditis, tumor chemotherapy, and adverse drug reactions. Most of the primary studies were of good quality only in 1 SR of non-small-cell lung cancer. According to the OQAQ scores, the quality of included SRs was variable and six reviews were of high quality with a score of 5 points. Two SRs showed that SMI had low adverse drug reaction occurrence. In conclusion, there is mixed evidence to support efficacy of SMI for an adjunct therapy to tumor chemotherapy and premature evidence for the use of SMI for cardio/cerebrovascular disorders and viral myocarditis. SMI seems generally safe for clinical application. Further large sample-size and well-designed RCTs are needed.
    Evidence-based Complementary and Alternative Medicine 02/2014; 2014:840650. DOI:10.1155/2014/840650 · 1.88 Impact Factor
Show more